Literature DB >> 25574082

Radiation therapy has been shown to be adaptable for various stages of hepatocellular carcinoma.

Yasuteru Kondo1, Osamu Kimura1, Tooru Shimosegawa1.   

Abstract

In addition to surgical procedures, radiofrequency ablation is commonly used for the treatment of hepatocellular carcinomas (HCCs) of limited size and number. Transcatheter arterial chemoembolization (TACE), using iodized poppy seed oil, Lipiodol and anticancer drugs, has been actively performed for the treatment of unresectable HCC, particularly in Asian countries. Recently, Sorafenib become available for advanced HCCs when the liver is still sufficiently functional. Sorafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects. However, the effect of sorafenib seems to be inadequate to control the progression of HCC. Radiation therapy (RT) for HCC has a potential role across all stages of HCC. However, RT is generally not considered an option in HCC consensus documents or national guidelines, primarily because of insufficient supporting evidence. However, the method of RT has much improved because of advances in technology. Moreover, combined treatment of RT plus other treatments (TACE, sorafenib and chemotherapy etc.) has become one of the alternative therapies for HCC. Therefore, we should understand the various kinds of RT available for HCC. In this review, we focus on various kinds of external beam radiation therapy.

Entities:  

Keywords:  Hepatocellular carcinoma; Radiation therapy; Radiofrequency ablation; Sorafenib; Transcatheter arterial chemoembolization

Mesh:

Year:  2015        PMID: 25574082      PMCID: PMC4284364          DOI: 10.3748/wjg.v21.i1.94

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  66 in total

1.  Treatment strategies for hepatocellular carcinoma in Japan.

Authors:  Tatsuya Yamashita; Shuichi Kaneko
Journal:  Hepatol Res       Date:  2012-05-14       Impact factor: 4.288

2.  Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma.

Authors:  Su Jung Shim; Jinsil Seong; Kwang Hyub Han; Chae Yoon Chon; Chang Ok Suh; Jong Tae Lee
Journal:  Liver Int       Date:  2005-12       Impact factor: 5.828

3.  Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.

Authors:  Wen-Yen Huang; Yee-Min Jen; Meei-Shyuan Lee; Li-Ping Chang; Chang-Ming Chen; Kai-Hsiung Ko; Kuen-Tze Lin; Jang-Chun Lin; Hsing-Lung Chao; Chun-Shu Lin; Yu-Fu Su; Chao-Yueh Fan; Yao-Wen Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-17       Impact factor: 7.038

4.  Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma.

Authors:  J I Herrero; B Sangro; J Quiroga; F Pardo; M Herraiz; J A Cienfuegos; J Prieto
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

5.  Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results.

Authors:  C Louis; S Dewas; X Mirabel; T Lacornerie; A Adenis; F Bonodeau; E Lartigau
Journal:  Technol Cancer Res Treat       Date:  2010-10

6.  Radioresponse of hepatocellular carcinoma-treatment of lymph node metastasis.

Authors:  Sang Min Yoon; Jong Hoon Kim; Eun Kyung Choi; Seung Do Ahn; Sang-wook Lee; Byong Yong Yi; Young Wha Chung; Young Sang Lee; Dong Jin Seo
Journal:  Cancer Res Treat       Date:  2004-02-29       Impact factor: 4.679

7.  Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

Authors:  Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Osamu Matsui; Michiie Sakamoto; Osamu Nakashima; Masamichi Kojiro; Masatoshi Makuuchi
Journal:  Dig Dis       Date:  2011-08-09       Impact factor: 2.404

8.  Combined therapy of transcatheter arterial chemoembolisation and three-dimensional conformal radiotherapy for hepatocellular carcinoma.

Authors:  Z-H Zhou; L-M Liu; W-W Chen; Z-Q Men; J-H Lin; Z Chen; X-J Zhang; G-L Jiang
Journal:  Br J Radiol       Date:  2006-10-12       Impact factor: 3.039

9.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

10.  Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: a meta-analysis of observational studies.

Authors:  Zheng Zheng; Wenhua Liang; Daniel P Milgrom; Zhouying Zheng; Paul M Schroder; Ning S Kong; Changsheng Yang; Zhiyong Guo; Xiaoshun He
Journal:  Transplantation       Date:  2014-01-27       Impact factor: 4.939

View more
  11 in total

Review 1.  Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Jeong Il Yu; Hee Chul Park
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

Review 2.  Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function.

Authors:  Taro Takami; Takahiro Yamasaki; Issei Saeki; Toshihiko Matsumoto; Yutaka Suehiro; Isao Sakaida
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

3.  Studied microRNA gene expression in human hepatocellular carcinoma by microRNA microarray techniques.

Authors:  Jian-Xiang Niu; Xing-Kai Meng; Jian-Jun Ren
Journal:  World J Gastroenterol       Date:  2015-11-28       Impact factor: 5.742

4.  Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant case report.

Authors:  Young-Hsiang Lin; Shih-Kai Hung; Wen-Yen Chiou; Moon-Sing Lee; Bing-Jie Shen; Liang-Cheng Chen; Dai-Wei Liu; Wei-Ta Tsai; Po-Hao Lin; Yi-Ting Shih; Feng-Chun Hsu; Shiang-Jiun Tsai; Michael W Y Chan; Hon-Yi Lin
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

5.  Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression.

Authors:  Cai Qun Bie; Xu You Liu; Ming Rong Cao; Qiu Yan Huang; Hui Jun Tang; Min Wang; Guo Li Cao; Ting Zhuang Yi; Sheng Lan Wu; Wei Jie Xu; Shao Hui Tang
Journal:  Oncotarget       Date:  2016-11-29

6.  Toll-like receptor 4 and its associated proteins as prognostic factors for HCC treated by post-radiotherapy surgery.

Authors:  Zhi-Feng Wu; Ying Wang; Ping Yang; Jia-Zhou Hou; Jian-Ying Zhang; Yong Hu; Zhao-Chong Zeng
Journal:  Oncol Lett       Date:  2018-04-26       Impact factor: 2.967

7.  Improved survival with radiotherapy in hepatocellular carcinoma with major vascular invasion: A propensity-matched analysis of Surveillance, Epidemiology, and End Results database.

Authors:  Qiuyan Lin; Xiaoquan Huang; Canmei Zhong; Tiancheng Luo; Xiaoqing Zeng; Shiyao Chen
Journal:  Cancer Med       Date:  2019-01-18       Impact factor: 4.452

8.  Transarterial Chemoembolization Followed by Radiotherapy Versus Sandwich Treatment for Unresectable or Ablative Hepatocellular Carcinoma.

Authors:  Haimin Lin; Huiyong Wu; Ning Cong; Bo Liu; Chengxin Liu; Dali Han
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 9.  Therapeutic Strategies in HCC: Radiation Modalities.

Authors:  R Gallicchio; A Nardelli; P Mainenti; A Nappi; D Capacchione; V Simeon; C Sirignano; F Abbruzzi; F Barbato; M Landriscina; G Storto
Journal:  Biomed Res Int       Date:  2016-08-03       Impact factor: 3.411

10.  PD-L1+MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment.

Authors:  Tomoaki Iwata; Yasuteru Kondo; Osamu Kimura; Tatsuki Morosawa; Yasuyuki Fujisaka; Teruyuki Umetsu; Takayuki Kogure; Jun Inoue; Yu Nakagome; Tooru Shimosegawa
Journal:  Sci Rep       Date:  2016-12-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.